(Q44073293)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Richard F. Kefford

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Helen Rizos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

J R Todd

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

L L Scurr

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

17 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

236-245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23246970%20AND%20SRC:MED&resulttype=core&format=json

Review: melanocyte migration and survival controlled by SCF/c-kit expression

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

KIT as a therapeutic target in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Major response to everolimus in melanoma with acquired imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

KIT pathway alterations in mucosal melanomas of the vulva and other sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562

Human melanocytes cultured from nevi and melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.562